The pipeline
17 programmes in development for hair loss and hair regeneration. Sorted by phase, latest first.
17 programmes
| Programme | Developer | Phase | Approach | Mechanism | Last activity |
|---|---|---|---|---|---|
| Minoxidil (low-dose oral) High· 4 trials | Unknown | Marketed, off-label | Oral | Potassium channel opener | 3 months ago |
| Baricitinib (Olumiant) High· 7 trials | Eli Lilly | Approved | Oral | JAK inhibitor | 1 month ago |
| Deuruxolitinib (Leqselvi) High· 10 trials | Sun Pharmaceutical | Approved | Oral | JAK inhibitor | 1 month ago |
| Dutasteride (Avodart / Zagallo) High· 9 trials | GSK | Approved | Oral | 5α-reductase inhibitor | 4 months ago |
| Finasteride (Propecia) High· 5 trials | Organon | Approved | Oral | 5α-reductase inhibitor | 8 months ago |
| Ritlecitinib (Litfulo) High· 15 trials | Pfizer | Approved | Oral | JAK inhibitor | 1 month ago |
| Upadacitinib (Rinvoq) High· 4 trials | AbbVie | Approved | Oral | JAK inhibitor | 1 month ago |
| Ivarmacitinib (ARQ-252) Medium· 2 trials | Unknown | Filed with regulator | Oral | JAK inhibitor | No public activity in over 18 months |
| AD-208 Low· 2 trials | Addpharma | Phase 3 | Oral | Undisclosed | No public activity in over 18 months |
| BL 3000 Low· 1 trials | Biolab Sanus Farmacêutica | Phase 3 | Oral | Undisclosed | No public activity in over 18 months |
| Jaktinib High· 4 trials | Suzhou Zelgen Biopharmaceuticals | Phase 3 | OralTopical | JAK inhibitor | 17 months ago |
| VDPHL-01 (oral minoxidil) Medium· 4 trials | Veradermics | Phase 3 | Oral | Potassium channel opener | 1 month ago |
| ASLAN003 Low· 1 trials | ASLAN Pharmaceuticals | Phase 2 | Oral | Undisclosed | No public activity in over 18 months |
| Brepocitinib Medium· 2 trials | Priovant Therapeutics | Phase 2 | Oral | JAK inhibitor | 3 months ago |
| Deucravacitinib High· 2 trials | Bristol Myers Squibb | Phase 2 | Oral | JAK inhibitor | 1 month ago |
| Etrasimod Medium· 1 trials | Pfizer | Phase 2 | Oral | Immunomodulator | No public activity in over 18 months |
| VC005 Low· 2 trials | Jiangsu Vcare Pharmaceutical | Phase 2 | Oral | Undisclosed | 1 month ago |